^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
ATLCAR.CD30 cell therapy
i
Other names: ATLCAR.CD30 cell therapy, ATLCAR.CD30 cells
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
UNC Lineberger Comprehensive Cancer Center
Drug class:
CD30-targeted CAR-T immunotherapy
Related drugs:
4years
Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL (clinicaltrials.gov)
P1/2, N=40, Recruiting, UNC Lineberger Comprehensive Cancer Center | Trial completion date: Feb 2037 --> Aug 2038 | Trial primary completion date: Feb 2022 --> Aug 2023
Trial completion date • Trial primary completion date
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 expression
|
TT11 • ATLCAR.CD30 cell therapy
over4years
Administration of T Lymphocytes for Prevention of Relapse of Lymphomas (clinicaltrials.gov)
P1, N=18, Recruiting, UNC Lineberger Comprehensive Cancer Center | Trial completion date: Sep 2034 --> Sep 2036 | Trial primary completion date: Apr 2020 --> Sep 2021
Trial completion date • Trial primary completion date
|
ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 expression • ALK negative • TNFRSF8 negative
|
ATLCAR.CD30 cell therapy
Share via
